Phase I/II dose-escalating trial of GEN 1 in combination with bevacizumab [Avastin] and liposomal doxorubicin [Doxil] in patients with platinum-resistant and recurrent ovarian cancer.
Phase of Trial: Phase I/II
Latest Information Update: 19 Apr 2016
At a glance
- Drugs GEN 1 (Primary) ; Bevacizumab; Doxorubicin liposomal
- Indications Ovarian cancer
- Focus Adverse reactions
- Sponsors Celsion Corporation
- 19 Apr 2016 According to a Celsion Corporation media release, this trial is expected to begin in fourth quarter of 2016.
- 12 Apr 2016 According to Celsion media release, this trial is expected to begin in the second half of 2016.
- 12 Oct 2015 According to Celsion media release, company is planning to initiate this trial in mid 2016.